A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: OTF 1Drug: OTF 2Drug: OTF 3Drug: OTF 4
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04300621
- Locations
- 🇧🇪
SGS Life Science Services, Antwerpen, Belgium
A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04282746
- Locations
- 🇧🇪
SGS Life Science Services, Antwerpen, Belgium
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
- Conditions
- Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04264806
- Locations
- 🇸🇦
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
🇨🇭UniversitaetsSpital Zuerich, Zürich, Switzerland
🇦🇺St Vincents Hospital Sydney, Darlinghurst, Australia
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04264884
A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04258189
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 476
- Registration Number
- NCT04252287
- Locations
- 🇺🇸
Mercy Clinic Cardiology - Fort Smith, Fort Smith, Arkansas, United States
🇺🇸Clearwater Cardiovascular Consultants, Clearwater, Florida, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT04235270
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT04225078
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT04223349
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- Conditions
- Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 85
- Registration Number
- NCT04210219
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇲🇩Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland